Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE)

Trial Profile

An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brazikumab (Primary) ; Brazikumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Acronyms Intrepid; INTREPID OLE
  • Sponsors AbbVie; Allergan; AstraZeneca; AstraZeneca AB

Most Recent Events

  • 24 Nov 2023 The trial has been completed in Germany (End Date: 19 Sep 2023), according to European Clinical Trials Database record.
  • 19 Oct 2023 Status changed from active, no longer recruiting to discontinued.
  • 06 Sep 2023 This trial has been discontinued in Spain (Global end date: 1 June 2023).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top